30Apr 2022
Effects of dapagliflozin on volume status and systemic hemodynamics in patients with CKD without diabetes: Results from DAPASALT and DIAMOND

Effects of dapagliflozin on volume status and systemic hemodynamics in patients with CKD without diabetes: Results from DAPASALT and DIAMOND

To assess the effect of SGLT2 inhibitor dapagliflozin on natriuresis, blood pressure (BP) and volume status in patients with CKD without diabetes. In DAPASALT (mean age 65 years, mean eGFR 39.4 ml/min/1.73m2, median UACR 111 mg/g), dapagliflozin did not change 24‐hr sodium and volume excretion during 2 weeks of treatment. During a standardized sodium diet, dapagliflozin decreased BP but did not increase 24‐hr sodium and volume excretion. The lack of increased natriuresis and diuresis may be attributed to the activation of intra‐renal compensatory mechanisms to prevent excessive water loss.

  • #endo-diabetology

Like

Save

Share